

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this PRELIMINARY AMENDMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service Mail Label NO. EL587946116US under 37 CFR 1.10 on the date indicated below and is addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Nancy L. Barker
Nancy L. Barker

5/15/01
Date of Deposit

Applicant: Kirkland, et al.)	
)	
Serial No.: Unassigned)	Group Art Unit: Unassigned
)	
Filed: May 15, 2001)	Examiner: Unassigned
)	
Title: MONOCLONAL ANTIBODIES)	
IMMUNOREACTIVE WITH)	Our Ref.: TSRI 372.0 Div. 2
LIPOPOLYSACCHARIDE BINDING)	
PROTEIN (LBP) AND METHODS)	
OF THEIR USE)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231
ATTN: BOX PATENT APPLICATION

Dear Sir:

Prior to examination of the above-identified patent application on the merits, which is a Divisional application of pending prior application U.S. Serial No. 09/081,350 filed under 37 CFR 1.53(b) concurrently herewith, please enter the following amendments.

IN THE SPECIFICATION

Please substitute the second sentence of the second full paragraph on page 13 with the following:

Particularly preferred is the monoclonal antibody Mab 2B5 produced by a hybridoma cell line having ATCC accession number HB 11491.

Please substitute the first and second sentences of the first full paragraph on page 65 with the following:

The murine hybridomas, designated Mab 1E8 and 2B5, were deposited on or before November 16, 1993, with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209 (ATCC). The 1E8 and 2B5 hybridomas have the respective ATCC Accession Numbers 11490 and 11491.

Attached hereto is Appendix A which includes the marked-up version of the changes to the Specification.

IN THE CLAIMS

Please cancel claims 15-19.

Please substitute the following claim 10 for the previously submitted claim 10:

10. (Amended) The monoclonal antibody of claim 9 produced by a hybridoma cell line having ATCC accession number HB 11491.

Attached hereto is Appendix A which includes the marked-up version of claim 10.

REMARKS

Claims 15-19 have been cancelled. Claims 1-14 and 20-35 are now pending. No new matter has been added.

Respectfully submitted,

5-14-01

Date

Thomas E. Northrup

Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937

[X] Attorney or agent of record
[] Filed Under §1.34(a)

APPENDIX AMARKED UP VERSION OF CHANGES IN SPECIFICATION

Second sentence of the second full paragraph on page 13:

Particularly preferred is the monoclonal antibody Mab 2B5 produced by a hybridoma cell line having ATCC accession number HB [_____] 11491.

First and second sentences of the first full paragraph on page 65:

The murine hybridomas, designated Mab 1E8 and 2B5, were deposited on or before November 16, 1993, with the American Type Culture Collection, [1301 Parklawn Drive, Rockville, MD, USA] 10801 University Blvd., Manassas, VA 20110-2209 (ATCC). The 1E8 and 2B5 hybridomas have the respective ATCC Accession Numbers [_____] 11490 and [_____] 11491.

MARKED UP VERSION OF CHANGES IN THE CLAIMS

10. The monoclonal antibody of claim 9 produced by a hybridoma cell line having ATCC accession number HB [_____] 11491.